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Residua! normal, highly proliferative progenitors can be isolated from the 
C D 34+/33— fraction of AML with a more differentiated phenotype (CD33+)
R Raymakers1, S W ittebol1, A Pennings1, E Linders1, P PoddigheJ and T, De W itte1
1 Division o f Hematology, Department o f Medicine; and 2Department of Pathology, University Hospital Nijmegen, The Netherlands
Since in AML differentiation is abnormal but not absent, a hier­
archy of stem cells, progenitor cells and more differentiated 
cells is postulated. The leukemic stem cell might also be 
characterized by the expression of CD34 and the absence of 
differentiation markers. Bone marrow samples of 33 AML pati­
ents, including 10 patients both at presentation and after 
relapse, were double labeled for CD34 and CD33. In 14/33 AML 
less than 1% of the labeled cells were found in the CD34+/33- 
fraction. After relapse a certain shift towards a more primitive 
phenotype was observed, but in 4/5 relapsed AML the 
CD34+/33- fraction remained below 1%. Single cells from the 
different subtractions were cultured and showed hetero­
geneous cluster and colony growth in both the CD34-/33+ and 
CD34+/33+ fraction. More colonies were observed in the 
CD34+/33- fraction. In AML with a more ‘mature5 phenotype 
(low number of CD344VCD33— cells), highly proliferative 
myeloid, erythroid and mixed colonies could be cloned exclus­
ively from this small CD34+/33- fraction. In five patients with 
numerical chromosomal abnormalities all these highly prolifer­
ative colonies appeared disomic using in situ hybridization 
(ISH) with centromeric probes. Based on these data we con­
clude that the CD34+/33- cell fraction in AML with a more 
mature immunophenotype (small fraction of cells CD34+/33-) 
comprise residual normal progenitors, while no primitive leu­
kemic progenitors could be identified.
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Introduction
In normal hematopoiesis the CD34+ population comprises 
the clonogenîc cells, ranging from stem cells to lineage com­
mitted progenitors. Primitive hematopoietic cells express 
CD34 and no lineage markers like CD33J The existence of a 
very primitive stem cell, w ith both hematopoietic potential 
and the possibility of stromal cell formation has been 
described to be a cell that phenotypically expresses CD34 and 
no lineage markers.2 During lineage commitment markers of 
the different pathways are co-expressed with CD34, while 
during further hematopoietic development both the proliferat­
ive capacity and CD34 expression are gradually lost.
AML is a clonal disease, which originates in either a pluri- 
potent stem cell or a lineage committed progenitor cell, for 
example a progenitor mainly restricted to the granulocytic 
pathway.3 This heterogeneity with respect to the pattern of 
differentiatlve expression suggests that at least in part of the 
AML the leukemic stem cell has features of a more differen­
tiated cell. Since the leukemic population regenerates, the 
cells must have acquired self-renewal capacity.
in normal bone marrow myeloid differentiation is charac­
terized by the appearance of CD33. In AML CD33 expression 
is observed in about 90% of the patients.4-5 However, since 
in AML hierarchy in development might be partially retained, 
the more primitive progenitor cells might also lack CD33
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expression. To answer this question CD34 and CD33 
expression in 33 AML patients was evaluated. Mononuclear 
cells were double stained with CD34-FITC and CD33-PE and 
single cells were sorted and cloned from the three different 
subfractions.
The single cell sorting method allows analysis of the off­
spring of individual colonies. Potential inhibitory effects of 
accessory cells could be excluded* Furthermore, it appeared 
that cells could be sorted from very small subpopulations (less 
than 1 : 1000) in leukemias that showed almost exclusively 
CD33+ cells. Weekly evaluation of the single wells gave 
information on the clonogenic capacity and the duration of 
proliferation, in patients with a numerical chromosomal aber­
ration (trisomy or monosomy) the individual colonies were 
checked for their origin by in situ hybridization (ISH).
Sorting and cloning from the different subpopulations 
revealed that in AML with a more mature immunophenotype, 
as referred to the hierarchy in normal hematopoiesis, the leu­
kemic clonogenic cells were observed in both the 
C D 34-/33+  and somewhat more frequently in the 
CD34+/33+ population. In the cells sorted from the small 
C D 34+/33- subpopulation residual normal colonies were 
found. This became apparent in the presence of SCF, which 
had a limited effect on leukemic growth but resulted in large 
colonies (5000-10000 cells) derived from highly proliferative 
progenitors with multilineage potential. The normal origin of 
the colonies was supported by ISH in a number of AML with 
numerical chromosomal aberrations.
Patients and methods
AML bone marrow samples
i
Bone marrow aspirates were obtained from 33 newly diag­
nosed and untreated patients. From 10 of these patients bone 
marrow was also collected after relapse and before 
retreatment. Aspirates were diluted in buffered acicl-citrate 
dextrose (pH 7.0). Nucleated cells were isolated from the 
aspirate by Ficoll (Sigma, St Louis, MO, USA) 1.077 g/ml den­
sity centrifugation. After washing twice with glucose-phos­
phate-buffered saline the interphase cells were resuspended 
in Iscove's medium (Flow Laboratories, Irvine, UK) with 10% 
(v/v) fetal bovine serum (FBS, Hyclone, Logan, UT, USA) and 
15 U/ml preservative-free heparin at a cell concentration of 
about 40 X 10(l cells/ml. This cell suspension was diluted 1 : 1 
with medium containing 20% DMSO (v/v) on ice. The cells 
were cryopreservecl (Kryo 10; PlanerBiomed, Sunbury, UK) in 
2-ml freezing tubes and stored at -198° C.
Thawing and labeling o f bone marrow cells
The vials were thawed rapidly in a 37° C waterbath, and 
diluted in FBS, containing 0.02 mg/ml DNAse (deoxy­
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ribonuclease I, grade II, from bovine pancreas, Boehringer- 
Mannheim, FRG) and 4 m  MgSot| and 15 U/ml preservative- 
free heparin. After washing, the cell pellet was incubated for 
30 min, 4° C, with 100 ¿¿I of monoclonal antibodies diluted 
in 10% pooled human serum (to reduce non-specific binding); 
anti-CD34-FITC 1 :'I0, (HPCA-2, Becton Dickinson, Oxnard, 
CA, USA) and anti-CD33-PE 1 :20 (My-9, Becton Dickinson). 
After labeling the ceils were washed once and diluted in glu- 
cose-phosphate buffer with 1% BSA.
Flow cytometric single cell sorting
The labeled cells were sorted by a Coulter Epics Elite Flow 
cytometer (Coulter, Hialeah, FL, USA) equipped with an auto­
clone unit. Cells were excitated with a single 488 nm Argon- 
ion laser running at 15 mW. Dichromic mirrors of 550 and 
625 nm and band pass filters 525/40 and 575/30 were used. 
A gate on the forward vs right angle light scatter diagram was 
used to exclude dead cells and debris. To standardize for flu­
orescence intensity and spectral overlap commercially avail­
able green and red fluorescent beads (Calibrite; Becton 
Dickinson, San lose, CA, USA) were used.
Culturing conditions o f the single cells in 96-well 
plates
Single ceils were sorted in roundbottom 96-well plates (Costar 
3799, Cambridge, MA, USA), prefilled with 74 ¡x 1 liquid 
medium, consisting of iscove's, penicillin 50 U/ml, strepto­
mycin 50 ju,g/mI (Fiow Laboratories) with 20% FBS, 5% deion­
ized bovine serum albumin (BSA), 0.3 mg/m! human trans­
ferrin and 5 X 10~r’ m 2-jS-mercaptoethanol. Recombinant 
growth factors were added, G-CSF (20 ng/ml) and SCF 
(25 ng/ml) (a gift from Amgen, Thousand Oaks, CA, USA), IL-3 
(50 ng/ml), GM-CSF (20 ng/ml) and erythropoietin (1.5 U/ml) 
(Eprex, Ciiag BV, Belgium). The plates were placed in an incu­
bator, 37° C, 5% C 0 2, in a fully humidified atmosphere.
Evaluation of growth and differentiation in the single 
wells
The cells in each individual well were counted under an 
inverted microscope. Due to the roundbottom configuration 
of the wells, the cells grew in the center of the well. One day 
after sorting single cells were found in about 90% of the wells. 
Counting was started at day 5 and repeated weekly until the 
colonies were fully differentiated, stopped growing or became 
pycnotic. Apart from the number of cells, the configuration 
of the cells while differentiating was noted as granulocytic, 
monocytic, erythroid and mixtures of these. To check for dif­
ferentiation the colonies from single wells were split and lab­
eled with Leucogate (CD45-FITC/CD14-PE)(BD) or CD15- 
FITC to differentiate monocytes from myelocytes and glyco- 
phorin to identify erythrocytes. Also colonies were cytocentri- 
fuged on slides and stained with May-Grunwald-Giemsa to 
check differentiation.
ISH for detection o f numerical chromosome 
aberrations
Cells picked from single wells were cytocentrifuged on 
organo-silane coated slides. Interphase cytogenetics on single
cell colonies was applied in seven AML patients with known 
numerical chromosome aberrations to check for the leukemic 
origin of the colonies.5,7
Fixation: The slides were heated for 30 min at 80° C. A 
proteolytic digestion with pepsin (P-7000; Sigma) was done 
at an optimized concentration of 100 /¿g/ml in O.O'i M MCI for
15 min at 37° C, Next, the slides were washed twice in 0.01 n  
HCl, dehydrated with increasing ethanol concentrations (70- 
90-100%) and postfixed in '1% formaldehyde in PBS for 5 
min. Then the slides were washed in PBS (five times) and H20  
(five times) and finally dehydrated again with increasing etha­
nol concentrations.
DNA probes and labeling: The different probes used in 
this study were D8Z2 for detection of chromosome 8,n 
pHUR98 for chromosome 9,° p i 0.1 for chromosome 10 H1 and 
p17H8 for chromosome 17.11 The DNA probes were 
hybridized to the cell preparations as described before7 in 
60% formamide, 2 X  SSC and 10% dextransulphate at a 
probe concentration of 1 ng/jul hybridization mixture. Ten 
microliters of the hybridization mixture were applied to the 
slides under a coversJip (18 X 18 mm). Denaturation of probe 
and target DNA was carried out simultaneously by heating the 
slides in a moist chamber to 70° C for 3 min. Hybridization 
was then performed overnight at 37° C in a moist chamber. 
The coverslips were removed by immersing the slides in 60% 
formamide, 2 X  SSC, pH 7.0. Next the sficles were washed 
three times for 5 min in the same buffer at 42° C and sub­
sequently three rimes for 5 min in 2 X SSC, pH 7.0 at 42° C.
The hybridized biotinylated probe was detected by horse­
radish peroxidase (HRP)-conjugated avidin (Dakopatts, 
Glostrup, Denmark) in 4 X SSC, 0.05% Tween 20 with 0.5% 
blocking milk (Boehringer Mannheim) and, if necessary, 
amplified with biotin-labeled goat-anti-aviclin (Vector, Bur­
lingame, CA, USA), followed by a second layer of HRP-conju- 
gated avidin. All immunocytochemical steps were performed 
for 30 min at 37° C. Finally the DNA probe waf visualized 
with 0.5 mg/ml 3,3-diaminobenzidintertahydrochloricle (DAB; 
Sigma), 0.65% imidazole (Merck, Darmstadt, FRG), 0.015% 
H20 2 (Merck), at pH 7.8 in PBS. Finally the cells were stained 
with mayers hematein.
Evaluation o f ISH results: Using the described ISH pro­
cedure at least 90% of the interphase nuclei showed one, two 
or three distinct ISH signals in all preparations. Evaluation cri­
teria were as described before.12 If possible at least 100 nuclei 
per slide were counted. The sensitivity of interphase cytogen­
etics in the detection of the targeted chromosomal abnor­
mality in case of monosomy varied by 5-10%, depending on 
the efficiency of the ISH procedure or the co-localization of 
two ISH signals. The detection of three ISH signals in normal 
cells is less than 1%.
Results
Expression o f CD34 and CD33 in AML
Cells of 33 untreated AML patients were double-labeled with 
CD34-FITC and CD33-PE. In the samples the percentage of
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blast ceils, detected morphologically on May-Griinwald- 
Giemsa stained cytospin slides, varied between 30 and 95%. 
Overall, 25% of the cells expressed CD34 (range <0.05 to 
92%) and 58% CD33 (range 0.6 to 96%).
The distribution of labeled cells between the subfractions 
C D 34-/33  +  , CD34-4-/33+ and C D 34 + /33 -, for all individ­
ual patients is presented in Figure 1. The individual samples 
are sorted for the frequency of CD344-/33— and as second 
parameter CD34+/33 + . The last bar represents the mean dis­
tribution found in normal bone marrow mononuclear cells 
(BM) (Ficoll 1.077 g/ml, n =  4): 76% (±4.2%) of the 
were C D 34-/33  +  , 13% (±3.3%) CD34+/33 + and 
(±0.6%) C D 3 4 + /3 3 -.
Trends in the distribution
cells 
11 %
gnized in AML for different 
are presented in Figure 2a
of CD34 and CD33 were reco- 
FAB types. Representative plots 
(untreated). In the only patient 
tested with AML-M1 and in all AML-M2 cases a high percent­
age of CD34+ cells were found, an average of 72%, The most 
primitive phenotype (if related to normal hematopoiesis) 
C D34+/33—, was observed in 16% of the cells, in AML-M3 
a comparable distribution was observed, 69% CD34+ and 
20% CD34-f/33—. A more 'differentiated' phenotype was 
seen in FAB-M4, 88% of the cells were CD34—/33 + . Further­
more, the cells that expressed CD34 were mainly 
CD34+/33 +  . This distribution was very consistently found in 
all M4 samples tested. In AML-M4e 57% and AML-M5 61% 
of the cells were CD34-/33-F, a substantial part was 
CD34+/33-F, while as in AML-M4 almost no C D 34+ /33- 
cells were detected.
Changes in  C D 3 4  a n d  C D 3 3  express ion  d u r in g  
re lapse
In 10 patients bone marrow aspirates were tested both before 
treatment and after relapse, to see whether relapse resulted in 
a higher percentage of cells with a more primitive phenotype 
(CD34-F/33 —, CD34-J-/33+) (Figure 3). The samples are 
sorted for the frequency of CD34-/33-F and CD34+/33-F 
cells in the untreated patients. This series included patients 
with early and late relapses. The overall percentage of CD34-F
cells increased from 50 to 59%. In 8/10 patients the relative 
number of CD34+ cells increased after relapse, but in 4/8 the 
increase was less than 10%. In two cases of AML a decrease 
of CD34-F cells of 14 and 17% was observed. Examples of 
fluorescence plots before and after relapse in some cases 
showed a clear shift to a more primitive immunophenotype 
(Figure 2a: untreated; 2b relapse).
In vitro g ro w th  o f  s ing le-sorted  ce lls  from  the d iffe re n t 
subfractions
Sorted single cells were cloned in 96-well plates, one plate for 
each fraction. To analyze in vitro growth recombinant growth 
factors IL-3, GM-CSF, G-CSF, erythropoietin and SCF were 
added. Both the plating efficiency (number of wells showing 
growth) and the size of the aggregates (number of cells/well) 
was highly variable, similar to observations of AML growth in 
conventional semi-solid cultures. To quantify growth charac­
teristics between the different phenotypic subfractions, the 
number of AML samples showing cluster growth (2-50 
cells/well) and colony growth (^50 cells/well) for each 
subfraction is given in Figure 4a and b, respectively. The 
actual plating efficiency (number of wells showing growth) in 
the different subfractions is presented in Table 1. Mean values, 
minimum and maximum numbers are given. As expected a 
large variation was observed.
In contrast to normal bone marrow growth was also seen 
in the CD3 4 -/3 3 +  fraction. In 75% of the AML samples clus­
ters and in 33% colonies could be grown. In the CD34+/33-F 
fraction the frequency of cluster and colony growth was some­
what higher, 91 and 44%, respectively. Most cluster and col­
ony growth was observed in the CD34H-/33- fraction, 96 and 
75%), respectively. The mean number of clusters and colonies 
showed a trend to increase in the more primitive phenotypic 
subfractions, 10.5 clusters and 3 colonies in the CD34-/33 + 
plate, 21.9 and 4.7 in the CD344-/33+ fraction and 19.6 and 
6.6 in the CD34+/33~ fraction. This trend was observed also 
in normal bone marrow, 24 clusters and 15 colonies in 
the CD34+/33-F fraction and 27 and 22 in the CD34+/33 — 
fraction.
100%
80% -
60% -
40% -
20%  -
0%
CD33-/34+
□  CD33+/34+
■  CD33+/34-
Figure 1 Distribution of the CD 34 and CD33 positively labeled AML cells among the different fractions. Sorting of the samples for increasing 
size of the CD34+/33 — and secondly C D 34+/33+  fraction. The right hand bar represents the distribution in normal bone marrow (BM) (n ~  4 
different donors)
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Figure 2 Representative examples of CD34 and CD33 distribution 
in the different FAB subtypes at presentation (untreated) and afLer 
relapse. Although some shift can be observed, in the samples with a 
small CD34+/33”  fraction, this fraction remains small after relapse
Apart from clusters and colonies, aggregates of >500 cells 
were counted separately. Overall/ these larger colonies were 
observed more frequently in the more primitive subfractions, 
43% in the C D 34+/33- fraction, 25% in the CD34+/33 + 
and only 8% in the CD34— /33+ fraction (Figure 4c). In some 
AML with a substantial C D 34+/33- fraction, colonies 
between 500 and 5000 cells were observed. In AML with a 
small C D 34+/33- fraction (<5% of the cells in the 
CD34-F/33- fraction), large colonies of more than 5000 cells 
were cultured (10/28 samples tested). Since these colonies 
included mixed type and erythroid colonies it appeared 
suggestive that these colonies originate from residual normal 
progenitor cells.
Effect o f SCF on colony growth
The effect of addition of SCF to the combination of the recom­
binant growth factors IL-3, GM-CSF, G-CSF and erythropoietin 
was studied in 20 AML samples. In the absence of SCF, colon­
ies were observed in 12 of the 20 samples, increasing to 16/20 
after addition of SCF. The number of co lon ic  increased from 
an average of 2.4 (0-10) to 6 (0-36) (Table 2). Even more 
obvious was the effect on colonies of >5000 cells/well. W ith­
out SCF, in only two patients was such a large colony 
observed, in the presence of SCF in 10 patients, an average 
of 1.1 (0-7) colonies of >5000 cells was found.
ISH on colonies derived from single cells in patients 
with numerical chromosomal aberrations
The large colonies of >5000 cells found in the C D 34+/33- 
cell fraction included mixed colonies, both monocytic and 
myelocytic as well as erythroid and myelo-monocytic. Differ­
entiated cells of the myelo- and monocytic lineage were 
detected microscopically on slides derived from single colon­
ies by cytocentrifugation and stained with May-GrGnwald- 
Giemsa. The different patterns of differentiation recognized in 
the unstained colonies were checked in a number of represen­
tative colonies using flow cytometry after staining with leuc- 
ogate (CD45-FITC/CD14-PE) or CD15-FITC in combination 
with glycophorin-A-FITC and CD14-PE. Thus, monocytic 
(CD14+/CD15-, erythroid (glycophorin+) and different 
myeloid colonies could be distinguished.
To provide further support for the normal origin of the large- 
sized colonies of mixed morphology ISH was performed in 
five patients with known numerical chromosomal aberrations. 
The five patients included three patients with a trisomy 8 (all 
AML-M4), one with a trisomy 9 (AML-M5), and one showing 
a monosomy 17 (AML-M3). Data on the distribution of the 
cells in the CD34 and CD33~labeled fractions and growth in 
single cell assay are presented in Table 3. All five patients had 
a small subfraction of CD34+/33— cells, varying between 0.1 
and 2.3%. As shown in Table 4 classical cytogenetics showed 
normal metaphases in 0-38% of the evaluated cases. With 
ISH, performed on non-selected but viable cells, the percent 
of cells with an aberrant phenotype was between 14 and 90%.
As summarized in Table 4, the large (>5000 cells) single 
cell derived colonies grown from the CD34-F/33- fraction 
were alt disomic. In 3/5 of the patients a sufficient number of 
cells could be sorted from the CD34+/33— fraction for ISH. 
In comparison with the overall population this fraction was 
enriched for disomic cells, varying between 70 and 100% 
(Table 4). Additionally, single cell derived colonies and clus­
ters from two patients with numerical chromosomal aber­
rations, a patient with an AML-M7 and a monosomy 7 and a 
patient with an AML-M2 and a trisomy 10 were tested. The 
CD34+/33— fraction in these two patients was much larger, 
20 and 28%, respectively. In the patient with the monosomy 
7 colonies up to 200 cells were cultured, showing monosomy, 
in the patient with the trisomy 10 only clusters were found, 
showing trisomic cells.
Discussion
The presence of primitive and more differentiated progenitor 
cells was studied in 33 AML patients by double labeling with
453
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Figure 3 Distribution of the CD34 and CD33 labeled cells among the different fractions in 10 patients, both at presentation and relapse
CD34 and CD33. CD34 and CD33 was expressed on ail 
tested samples, but the percentage of labeled cells and the 
distribution between the different subfractions was highly vari­
able; this in contrast with normal bone marrow which showed 
a rather consistent distribution,
A certain correlation between FAB subtype and the distri­
bution of CD34 and CD33 was found. In AML M1, M2 and 
part of the M3 a substantial percentage of the cells were 
CD34H-/33—, the most primitive phenotype if compared with 
normal bone marrow. In AML M4, M5 and 3/5 M3 samples 
the majority of the cells were CD33 + . In these AML samples 
only a small fraction of the cells showed the most primitive 
C D 3 4 + /3 3 - phenotype. Ten patients were also studied at 
relapse, to see whether a substantial shift towards a more 
primitive phenotype had developed. According to literature 
data the percentage of CD34+ cells should be higher after 
relapse. Thomas et concluded that AML tended to relapse 
with a less differentiated phenotype. An increase in CD34+ 
celIs was observed in 8/10, but in only 4/8 samples was the 
increase more than 10%. In some individual samples a sub­
stantial shift to the more primitive phenotype was observed, 
for example in the patient with AML M l (see Figure 2). How­
ever, in AML patients with a small C D 3 4 + /3 3 - fraction (less 
than 1%) no increase was observed after relapse. These obser­
vations and data from the literature suggest that an only lim­
ited hierarchy in immunophenotype is present in AML.
The next question to address was whether this hierarchy 
also implicated that cells from the more primitive phenotypic 
subfractions were progenitors with a higher proliferative 
capacity and possibly self-renewal capacity. The results of sin­
gle cell sorting and cloning from the different phenotypic 
subtractions showed that in general the cloning efficiency was 
highly variable for each individual AML sample. Cluster 
growth predominated, which is also observed in conventional 
semi-solid cultures. Cluster and colony growth was more or 
less comparable in the CD34-/334- and CD34+/33+ frac­
tion. This is in contrast to normal bone marrow showing no 
growth in the CD34-/33-4- fraction, In the most primitive 
C D 3 4 + /3 3 - fraction both the number and the frequency of 
colony (not cluster) growth was higher. The colonies in this 
fraction often were very large colonies of 5000-10 000 cells 
and of myeloid, erythroid and mixed morphology. Interest­
ingly, such highly proliferative colonies were found exclus­
ively in AML that showed a very small C D 34+/33- subtrac­
tion. The growth of these large colonies was sustained for up 
to 4-6 weeks. In contrast the leukemic clusters and colonies 
stopped proliferating and became pycnotic after 1-2 weeks. 
To further analyze the origin of these single-cell derived highly 
proliferative colonies, ISH was applied in five patients show­
ing numerical chromosomal aberrations in their leukemic 
cells. All these highly proliferative colonies were disomic. The 
size, duration of proliferation, mixed morphology and the dis­
omy in the offspring support the idea that these colonies are 
residual normal colonies. In two AML patients with numerical 
chromosomal aberrations and a larger CD34+/33— subfrac­
tion (20 and 28%, corresponding to a more primitive 
immunophenotype), both the clusters and colonies did show 
the numerical aberration. In these samples the colony size did 
not exceed 200 cells, the colonies were monomorphic in their 
differentiation and stopped proliferating after 7-10 days.
The high proliferative capacity of the progenitors cultured 
in more mature AML from the CD34+/33 — fraction became 
apparent after the addition of SCF to the culture medium with 
IL-3, GM-CSF, G-C5F and erythropoietin. Using this combi­
nation of growth factors the colonies reached a size of 5000- 
10000 cells. It has to be emphasized that SCF also increased 
the leukemic colonies and clusters in about half the AML 
samples. Thus the potentiating effect of SCF is not specific for 
the normal cell population.
The presence of residual normal colonies in AML bone mar­
row and especially the progenitors that showed a high pro­
liferative capacity in the presence of SCF has implications for 
studying the effect of SCF in vitro. For example, Ikeda et a/14 
described the effect of SCF on AML bone marrow samples 
cultured in liquid. They describe that SCF promoted pro­
longed growth of AML and differentiation into various cell lin­
eages. They concluded that SCF changes phenotypic commit­
ment. We postulate that their cultures contained residual 
normal cells that were quantatively low, but after addition of 
SCF started to proliferate substantially. Since in our study a 
single cell culturing system was used, inhibitory effects of the 
AML cells on the growth of residual normal progenitors could 
be excluded. Such effects have been described, for example 
in AML producing TNFa.13
Residual normal colonies have been observed in full blown 
AML bone marrow samples before. Bernstein et aP found in
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Figure 4 The percentage of AML showing growth of clusters (a) and colonies (b) in the phenotypic subtractions: CD34~V334~, CD34+/33 + 
and CD34+/33“ . (c) Percentage of AML that showed large colonies (>500 cells) and colonies that are considered to be highly proliferative, 
residual normal colonies
3/4 AML patients immature and non-clonai (using G6PD as a 
marker) cells in the C D 34+/33- fraction after culturing in a 
long-term culturing system. The cells of the colonies in the 
fourth patient were clonal. Their findings are confirmed in our 
study. The single cell system with prolonged follow-up for 4 -  
6 weeks showed similar results as their long-term culturing 
system. In addition, we showed the finding of residual normal 
progenitors to be correlated with the immunophenotype of the 
leukemia. In AML with a more primitive immunophenotype 
no highly proliferative colonies were cultured In the presence 
of SCF. Residual normal progenitors in the CD34+/33- frac­
tion do not exclude the presence of leukemic (clonogenic) 
cells in that fraction. For that reason ISH was performed also 
on directly sorted cells from the C D 34+/33- population in 
patients with a more differentiated phenotype. In 2/5 the frac­
tion was too small to sort enough cells for ISH. In one patient 
all cells from the C D34+/33— fraction were disomic, while 
in two patients cells with the numerical aberration were also 
detected. Further study with more sensitive and better dis­
criminating AML markers such as specific translocations (eg 
t(15;17), t(8;21)) will probably demonstrate the purity of the 
subfraction. An explanation for admixture of the CD34+/33 — 
fraction with leukemic cells can be a technical limitation, the 
low frequency (1 :1000-10 000) of sorted cells increases the 
change of admixture with cells not in the sorting window. Fur­
thermore, a negative selection for the CD33 marker holds the 
risk of admixture of incompletely labeled cells.
The data from this study cannot exclude leukemic stem cells 
to be present at a low frequency in the C D 34+ /33 - fraction 
even in AML with a more differentiated phenotype. It may be
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Table 1 Growth in the phenotypic subfractions in single cell assay in 32 AML patients and normal bone marrow
Cells/Well CD34-/33+ CD34+/33+ CD34+/33~
>2 >50 >500 > 2 >50 >500 >2 >50 >500
AML M2 10.2 (0-69) 4.5 (0-43) 2.8 (0-28) 27.8 (0-67) 6.2 (0-45) 2.8 (0-32) 21.3 (3-46) 3.6 (0-26) 2 (0-20)
AML M3 8 (0-16) 2(0-4) 0 10.8 (0-42) 7 (0-27) 0.25 (0-1) 13.8 (3-23) 9.4 (0-19) 3.2 (0-8)
AML M4 14 (0-55) 2.1 (0-17) 0 15.6 (1-37) 2.6 (0-16) 0.6 (0-3) 17.8 (3-23) 8.4 (1-15) 5 (1-10)
AML M4e 8 (0-23) 3(0-9) 0.3 (0-1) 36.7 (13-51) 8 (0-24) 0.3 (0-1) 15 0 0
AML M5 4 1 0 6 (3-11) 1 (0-2) 0.7 (0-2) 36.5 (20-53) 22.5 (9-36) 14.5 (2-27)
AML overall 10.5 (0-69) 3 (0-43) 1.1 (0-28) 21.9 (0-69) 4.7 (0-45) 1.3 (0-32) 19.6 (0-53) 6.6 (0-36) 3.4 (0-27)
BM (n = 4) 0 (0-1) 0 0 24 (10-38) 15 (6-32) 8 (3-25) 27 (10-42) 22 (8-33) 13 (5-28)
Cells from the phenotypic subfractions after labeling with CD33 and CD34 were single cell sorted and cloned. The mean number of wells 
(minimum and maximum) that contain clusters (>2 cells/well), colonies (>50 cells/well) and large colonies (>500 cells/well) are shown
Table 2 Effect of the addition of SCF to single cell cultures from AML patients
> 2 Cells/Well > 10 Celfs/Weil >50 Cells/Well >500 Cells/Weil >5000 Ceils/Well
No SCF 11.8 8.2 2.4 0.7 0.1
(0-41) (0-35) (0-10) (0-4) (0-1)
SCF 18.9 12.6 6 3.1 1.1
(0-53) (0-48) (0-36) (0-23) (0-7)
Mean number of wells showing clusters and colonies (between brackets minimum and maximum number observed) after stimulation with 
GM-CSF + G-CSF + IL-3 + Epo and after addition of SCF to this combination. Results of the CD34+/33- fraction that included residual 
normal colonies
Table 3 Distribution of the CD34 and CD33 labeled cells (size of the fractions) and growth in single cells assay (percentage of wells with 
>10/50/500/5000 cells) in five patients with known numerical chromosomal aberrations, informative for ISH analysis
CD34--/33+ fraction CD34+/33+ fraction CD34+/33— fraction
Size % Growth (% of wells) Size % Growth (% of wells) Size % Growth (% of wells)
>10 >50 >10 >50 >500 >10 >50 >500
1 59 0 0 39 0 0 0 2.3 23 19 5
2 77 0 0 23 2 0 0 0.1 17 15 3
3 99.5 2 0 0.4 2 0 0 0.1 2 1 1
4 70 1 0 30 17 1 0 0.3 16 11 2
5 95 ND 4 2 2 2 1 48 36 7
ND, not done
that these leukemic stem cells do not proliferate under the 
given in vitro circumstances. This is also suggested by Lapidot 
et a/16 who transplanted cells from the phenotypicaily most 
primitive fraction (C D 34+ /38 -) into SCfD mice and found 
initiation of human AML almost exclusively if cells from this 
fraction were used. Human AML were transplanted to SCID 
mice from different, also more differentiated AML. However, 
the C D 34+/38— cells were used only in an AML-M1, an 
example of a leukemia with a more primitive phenotype. 
Transplantation of C D 34+/38— cells from an AML with a 
more differentiated phenotype has not been described. The 
practical implication is the usefulness of antiCD33 in AML 
with a more mature immunophenotype to purge leukemic
cells. This approach has been applied in vitro in transplants 
for autologous reinfusion17 and also in vivo using 131 l-labeled 
anti-CD33.in It is too early to prove the value of this approach.
In conclusion, this study shows that in AML a limited hier­
archy in phenotypic make-up exists. Leukemia cluster and 
colony growth was observed in all phenotypic subfractions, 
also in the CD34—/33+ fraction showing no colony growth 
in normal bone marrow. Most colony growth was seen in the 
CD34+/33 — population. However, the large colonies cul­
tured from the very small CD34+/33— cell fraction in AML 
with a more mature immunophenotype most probably are 
residual normal colonies. In the presence of SCF and after pro­
longed in vitro culturing these highly proliferative colonies
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Table 4 Cytogenetics and IS! I in five patient samples with known numerical chromosomal aberrations and large colonies in the CD34+/33 
fraction, expected to be residual normal colonies
Patient FAB Cytogenetic findings Aberrant phenotype detected by ISH
ND, not done; the cell number in the sorted CD344-/33- fraction was too low (see text)
Numer/caf
aberration
Normal
metaphases
All viable 
cells
CD34+/33-  
sorted cells
Colonies from 
CD34+/33- cells
1 M3 Mono 17 M l 26% 18% 0/16
2 M4 Tris 8 1/13 14% ND 0/11
3 M4 Tris 8 5/13 20% 0% 0/6
4 M4 Tris 8 0/10 90% ND 0/14
5 M5 Tris 9 0/13 18% 9% 0/9
became apparent. All the highly proliferative and prolonged 
proliferating colonies were disomic in patients with numerical 
chromosomal aberrations in their AML. No definitive answer 
could be given on the purity of the CD34+/33- cells as 
residual normal progenitors or the presence of leukemic stem 
cells, that may be non-clonogenic in the culturing system 
used. Sorting and cloning in SCID mice of cells from this 
CD344733 — fraction in CD33+ AML has to be performed to
answer this question.
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